**Author Information** An event is serious (based on the ICH definition) when the patient outcome is:\* death\* life-threatening\* hospitalisation\* disability\* congenital anomaly\* other medically important event\* Drug interaction

In a study consisting of 50 patients who were treated with hydroxychloroquine and azithromycin from 18^th^ March 2020 to 25^th^ March 2020, one patient \[*age and sex not stated*\] was described, who developed acute QT interval prolongation following concomitant administration of hydroxychloroquine and azithromycin as off-label therapy for COVID-19.

The patient was hospitalised with COVID-19 pneumonia. The patient started receiving off-label treatment with hydroxychloroquine and azithromycin. Hydroxychloroquine was scheduled to be administered at a dose of 600 mg/d for 10 days and azithromycin was scheduled to be administered at a dose of 500 mg/d on day 1 and 250 mg/d from day 2 to day 5 \[*routes not stated*\]. Subsequently, a 12-lead ECG showed QT interval prolongation. The acute QT interval prolongation was considered to have developed secondary to drug interaction between hydroxychloroquine and azithromycin \[*time to reaction onset not stated*\].

Therefore, the patient discontinued hydroxychloroquine and azithromycin. On day 2 after discontinuation of hydroxychloroquine and azithromycin, the patient\'s QT interval was found to be stable at 500ms. Thereafter, the patient was discharged.
